These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35921798)

  • 61. Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba.
    Medina EAG; Caballero BB; Miguel KL; Gutiérrez ZA; Fernández BM; Tul LEA; Rodríguez LEM; Guerrero OV; Varela IGS; Bernardo MCC; Montero YC; Ortiz MR; Carrasco JM; Torres KP; Prado YID; Rubio MC; Braojo IMP
    Cancer Treat Res Commun; 2023; 34():100670. PubMed ID: 36549232
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
    Piccart M; Procter M; Fumagalli D; de Azambuja E; Clark E; Ewer MS; Restuccia E; Jerusalem G; Dent S; Reaby L; Bonnefoi H; Krop I; Liu TW; Pieńkowski T; Toi M; Wilcken N; Andersson M; Im YH; Tseng LM; Lueck HJ; Colleoni M; Monturus E; Sicoe M; Guillaume S; Bines J; Gelber RD; Viale G; Thomssen C;
    J Clin Oncol; 2021 May; 39(13):1448-1457. PubMed ID: 33539215
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
    Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
    Front Immunol; 2022; 13():877825. PubMed ID: 35663978
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
    Swain SM; Kim SB; Cortés J; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Knott A; Clark E; Ross G; Benyunes MC; Baselga J
    Lancet Oncol; 2013 May; 14(6):461-71. PubMed ID: 23602601
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
    Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
    JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
    Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
    Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
    Stoen E; Kagihara J; Shagisultanova E; Fisher CM; Nicklawsky A; Kabos P; Borges VF; Diamond JR
    Breast Cancer Res Treat; 2021 Jun; 187(3):883-891. PubMed ID: 33625615
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
    Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Hegg R; Tausch C; Seo JH; Tsai YF; Ratnayake J; McNally V; Ross G; Cortés J
    Ann Oncol; 2013 Sep; 24(9):2278-84. PubMed ID: 23704196
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
    Chung C; Lam MS
    Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
    Zhou M; Wang S; Wan N; Yuan S; Hu X; Zhou W; Qing B; Liu M; Sun W; Fan P; Wang J; Cao H; Xu H; Dai B; Tang P; Qian L; Zhao X; Xiao J; Zhou H; Hu J; Ding L; Tripodi D; Zdenkowski N; O'Keefe TJ; Sanchez AM; Chen L; Zhang P; Xu F
    Ann Transl Med; 2022 Dec; 10(24):1387. PubMed ID: 36660637
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.
    Liu X; Liu Z; Li C; Song X; Wang X; Li S; Yu Z
    World J Surg Oncol; 2023 Sep; 21(1):296. PubMed ID: 37723497
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
    Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
    N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
    Guardia C; Bianchini G; Arpí-LLucià O; Menendez S; Casadevall D; Galbardi B; Dugo M; Servitja S; Montero JC; Soria-Jiménez L; Sabbaghi M; Peña R; Madoz-Gúrpide J; Lloveras B; Lluch A; Eroles P; Arribas J; Pandiella A; Gianni L; Rojo F; Rovira A; Albanell J
    Clin Cancer Res; 2021 Sep; 27(18):5096-5108. PubMed ID: 34385295
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
    Baselga J; Gelmon KA; Verma S; Wardley A; Conte P; Miles D; Bianchi G; Cortes J; McNally VA; Ross GA; Fumoleau P; Gianni L
    J Clin Oncol; 2010 Mar; 28(7):1138-44. PubMed ID: 20124182
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
    Rayson D; Gandhi S; Joy AA; Brezden-Masley C; Gelmon KA; Sehdev S; Cescon D; Chia S
    Curr Oncol; 2022 Dec; 29(12):9891-9895. PubMed ID: 36547192
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.